259 related articles for article (PubMed ID: 17303913)
1. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
[TBL] [Abstract][Full Text] [Related]
4. [Hormonal therapy and chemotherapy of endometrial cancer].
Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate.
Fung MF; Krepart GV; Lotocki RJ; Heywood M
Obstet Gynecol; 1991 Dec; 78(6):1033-8. PubMed ID: 1945203
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapy for women with stage IA endometrial cancer of all grades.
Park JY; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Obstet Gynecol; 2013 Jul; 122(1):7-14. PubMed ID: 23743459
[TBL] [Abstract][Full Text] [Related]
8. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
[TBL] [Abstract][Full Text] [Related]
9. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
11. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy in metastatic or recurrent endometrial carcinoma].
Deppe G; Baumann P; Munkarah A
Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705
[TBL] [Abstract][Full Text] [Related]
13. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
Nakayama K; Ishikawa M; Nagai Y; Yaegashi N; Aoki Y; Miyazaki K
Int J Clin Oncol; 2010 Apr; 15(2):179-83. PubMed ID: 20217451
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study.
Pinelli DM; Fiorica JV; Roberts WS; Hoffman MS; Nicosia SV; Cavanagh D
Gynecol Oncol; 1996 Mar; 60(3):462-7. PubMed ID: 8774658
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Mountzios G; Bamias A; Voulgaris Z; Rodolakis A; Vlahos G; Gourgoulis G; Papaiakovou EE; Giannopoulos A
Gynecol Oncol; 2008 Jan; 108(1):130-5. PubMed ID: 17988722
[TBL] [Abstract][Full Text] [Related]
16. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA
Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for endometrial cancer.
Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]